Navigation Links
Study shows steroid therapies following transplant can be eliminated

CINCINNATIA new study by researchers at the University of Cincinnati (UC) shows that using modern immunosuppressive drugs eliminates the need for steroid therapy as early as seven days following a transplant surgery while still maintaining kidney function.

Steve Woodle, MD, chief of UC's transplant surgery division, principal investigator and designer of the study, says the elimination of a daily dose of steroids following transplantation minimizes chronic health conditions common to kidney transplant recipients.

The datafrom what is believed to be the longest-running, double-blinded study of its kind in the transplant fieldis published in the October issue of the Annals of Surgery.

"Steroids have long been the primary source of morbidity and complications following successful kidney transplantation," Woodle says. "This study demonstrates that elimination of even small, daily prednisone (pred-ne-zone) doses does not compromise results while minimizing weight gain, diabetes and bone complications."

Corticosteroids were the first anti-rejection drug used in transplant patients, dating back to the first transplant surgeries over 50 years ago.

Traditionally patients who have undergone organ transplantation have required life-long steroid treatments given in combination with other drugs that help suppress the body's immune system and allow the transplanted organ to function properly.

However, the steroid treatmentgiven as the oral drug, prednisonecan cause serious side effects including cardiovascular disease, high cholesterol and blood pressure, weight gain, diabetes, bone weakness and cataracts.

To test the effectiveness of early elimination of steroids, researchers studied 397 patients from 25 U.S. kidney transplant centers for a five-year period following transplant. They administered low doses of prednisone to one group of transplant patients while the other group of patients received a placebo.

The results showed that early steroid elimination caused reduction in many steroid-related complications, even when prednisone was given in very low doses.

Kidney function was similar in both patient groups.

"By demonstrating identical kidney transplant survival and function for five years, we now have a scientific basis for offering steroid-free therapies in kidney recipients," Woodle says.

However, he notes that risk of rejection episodes in patients was slightly increased with early steroid discontinuation.

"These episodes were mild and easily treated," he says.

He adds that although the five-year kidney transplant survival and function were identical between those who received prednisone and those who received other immunosuppressive drugs in this study, it doesn't mean that it will be the same in 10 or 20 years.

"Our hope is that with our modern anti-rejection drugs and new drugs being developed, even this small risk of increased rejection combined with longer-term results will not be changed," he says.

The results of this study are now being used in different transplant populations, resulting in much lower prednisone doses or complete elimination with fewer complications.


Contact: Katie Pence
University of Cincinnati

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: